Abstract
Recent clinical trials of immunotherapies indicate that tumor reactive autologous T cells are able to regress even advanced, large tumors in melanoma patients. For example, the adoptive transfer of CD8+ cytotoxic T lymphocytes (CTL) specifically targeted for identified tumor antigens following lymphodepletive treatment, such as fludarabine/cyclophosphamide administration and total body irradiation, led to objective tumor responses in more than 70% of patients with melanoma (Dudley et al. 2008). Immunological analyses on these tumor tissues demonstrated that administered T cells may eliminate tumor cells through direct killing and cytokine secretion. Therefore, CD8+ CTLs that recognize MHC class I positive cancer cells are important for in vivo tumor rejection.
Original language | English |
---|---|
Title of host publication | Innate Immune Regulation and Cancer Immunotherapy |
Publisher | Springer New York |
Pages | 335-345 |
Number of pages | 11 |
ISBN (Print) | 9781441999146, 9781441999139 |
DOIs | |
Publication status | Published - 2012 Jan 1 |
ASJC Scopus subject areas
- Medicine(all)